Related Experiment Video
Updated: Jan 11, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Novel Tricyclic Compounds as TLR7 Agonists for Treating Cancer
1Arclin USA LLC, 1150 Sanctuary Parkway, Suite 100, Alpharetta, Georgia 30009, United States.
Abstract:
Provided herein are novel tricyclic compounds as TLR7 agonists, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...